AstraZeneca PLC, Novo Nordisk A/S Investors Pin Hopes on Data from Two Closely-Watched Trials

Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.

AstraZeneca wants to prove its blood-thinner Brilinta can help stroke patients, in addition to those with heart problems, while Novo aims to showcase the cardiovascular benefits of its blockbuster diabetes treatment Victoza.

While positive outcomes are not guaranteed, industry analysts believe AstraZeneca may have the easier task.

Back to news